Stimuli-Responsive mRNA Vaccines to Induce Robust CD8 + T Cell Response via ROS-Mediated Innate Immunity Boosting
Journal of the American Chemical Society · 2024
DOI: 10.1021/jacs.4c04331 ↗At a glance
Journal article in Journal of the American Chemical Society, 2024. Written by Linying Dong and 10 co-authors. Institution: Medical School, Faculty of Medicine, Tianjin University, Tianjin 300072, China. Major MEDLINE topics: Reactive Oxygen Species, Immunity, Innate, CD8-Positive T-Lymphocytes. Cited 40 times so far (Crossref); 46 references. Funded by: National Key Research and Development Program of China, National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province.
Abstract (original language)
The messenger RNA (mRNA) vaccines hold great significance in contagion prevention and cancer immunotherapy. However, safely and effectively harnessing innate immunity to stimulate robust and durable adaptive immune protection is crucial, yet challenging. In this study, we synthesized a library of stimuli-responsive bivalent ionizable lipids (srBiv iLPs) with smart molecular blocks responsive to esterase, H2O2, cytochrome P450, alkaline phosphatase, nitroreductase, or glutathione (GSH), aiming to leverage physiological cues to trigger fast lipid degradation, promote mRNA translation, and induce robust antitumor immunity via reactive oxygen species (ROS)-mediated boosting. After subcutaneous immunization, esterase-responsive vaccine (eBiv-mVac) was rapidly internalized and transported into the draining lymph nodes. It then underwent fast decaging and self-immolative degradation in esterase-rich antigen-presenting cells, releasing sufficient mRNA for antigen translation and massive reactive quinone methides to elevate ROS levels. This resulted in broad activation of innate immunity to boost T cell response, prompting a large number of primed antigen-specific CD8+ T cells to circulate and infiltrate into tumors (>1000-fold versus unvaccinated control), thereby orchestrating innate and adaptive immunity to control tumor growth. Moreover, by further combining our vaccination strategy with immune checkpoint blockade, we demonstrated a synergism that significantly amplified the magnitude and function of antigen-specific CD8+ T cells. This, in turn, caused potent systemic antitumor efficacy and prolonged survival with high complete response rate in xenograft and metastasis models. Overall, our generalized stimuli-responsive mRNA delivery platform promises a paradigm shift in the design of potent vaccines for cancer immunotherapy, as well as effective and precise carriers for gene editing, protein replacement, and cell engineering.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Medical School, Faculty of Medicine, Tianjin University, Tianjin 300072, China.
- Zhejiang Cancer Hospital, The Key Laboratory of Zhejiang Province for Aptamers and Theranostics, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China.
- Molecular Science and Biomedicine Laboratory (MBL), State Key Laboratory of Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha 410082, China.
- Institute of Molecular Medicine (IMM), Renji Hospital, Shanghai Jiao Tong University School of Medicine, and College of Chemistry and Chemical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China.
ORCID profiles: Penghui Zhang, Weihong Tan
Funding
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province
- Scientific Experiment Center, Hangzhou Institute of Medicine, Chinese Academy of Sciences
- Zhejiang Leading Innovation and Entrepreneurship Team
Cite
APA
Dong, L., Deng, X., Li, Y., Zhu, X., Shu, M., Chen, J., Luo, H., An, K., Cheng, M., Zhang, P., & Tan, W. (2024). Stimuli-Responsive mRNA Vaccines to Induce Robust CD8 + T Cell Response via ROS-Mediated Innate Immunity Boosting. Journal of the American Chemical Society. https://doi.org/10.1021/jacs.4c04331
Vancouver
Dong L, Deng X, Li Y, Zhu X, Shu M, Chen J, et al. Stimuli-Responsive mRNA Vaccines to Induce Robust CD8 + T Cell Response via ROS-Mediated Innate Immunity Boosting. Journal of the American Chemical Society. 2024. doi:10.1021/jacs.4c04331
BibTeX
@article{Dong2024,
author = {Dong, Linying and Deng, Xuqian and Li, Yan and Zhu, Xiaolan and Shu, Mingbo and Chen, Jingyi and Luo, Huacheng and An, Keli and Cheng, Ming and Zhang, Penghui and Tan, Weihong},
title = {Stimuli-Responsive mRNA Vaccines to Induce Robust CD8 + T Cell Response via ROS-Mediated Innate Immunity Boosting},
journal = {Journal of the American Chemical Society},
year = {2024},
doi = {10.1021/jacs.4c04331}
}
EUVIMED